STXBP5L

Across TCGA pan-cancer cohorts, STXBP5L mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated STXBP5L data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher STXBP5L mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated STXBP5L expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where STXBP5L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.947	0.257	.020	8	view →
LUAD	DFS	Median	All	0.411	0.849	.036	2	view →
GBM	DFS	Median	All	0.823	0.673	.015	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

STXBP5L–CCRCC (DFS)

Open the CCRCC breakdown →